Transitioning patients with severe haemophilia A from emicizumab prophylaxis to valoctocogene roxaparvovec gene therapy: Real-world clinical experience

被引：0
|
作者：
Klamroth, Robert [1 ,2 ,3 ]
Gottstein, Saskia [1 ]
机构：
[1] Vivantes Clin Friedrichshain, Internal Med Vasc Med & Haemostaseol, Berlin, Germany
[2] Univ Bonn, Univ Hosp Bonn, Inst Expt Hematol & Transfus Med, Med Fac, Bonn, Germany
[3] Univ Bonn, Med Fac, Bonn, Germany
来源：
HAEMOPHILIA | 2024年 / 30卷 / 05期
关键词：
D O I：
10.1111/hae.15086
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1247 / 1249
页数：3
相关论文
共 50 条
  • [1] Transitioning from emicizumab prophylaxis to valoctocogene roxaparvovec gene therapy: A simulation study for individuals with severe haemophilia A
    Agarwal, Suresh
    Hermans, Cedric
    Miesbach, Wolfgang
    Peyvandi, Flora
    Sidonio Jr, Robert
    Osmond, Dane
    Newman, Vanessa
    Henshaw, Josh
    Pipe, Steven
    HAEMOPHILIA, 2024, 30 (04) : 905 - 913
  • [2] INVASIVE PROCEDURES IN PATIENTS WITH HAEMOPHILIA ON EMICIZUMAB PROPHYLAXIS: REAL-WORLD CLINICAL EXPERIENCE IN SLOVENIA
    Rener, K.
    Pompe, B.
    Doma, S. Anzej
    Kotnik, B. Faganel
    Kitanovski, L.
    Zupan, I. Preloznik
    HAEMOPHILIA, 2022, 28 : 66 - 66
  • [3] Matching-adjusted indirect comparison of bleeding outcomes in severe haemophilia A: Comparing valoctocogene roxaparvovec gene therapy, emicizumab prophylaxis, and FVIII replacement prophylaxis
    Astermark, Jan
    Buckner, Tyler W.
    Frenzel, Laurent
    Hatswell, Anthony J.
    You, Xiaojun
    Liu, Hai
    Goodman, Erin
    Santos, Sandra
    Hawes, Charles
    Hinds, David
    Klamroth, Robert
    HAEMOPHILIA, 2023, 29 (04) : 1087 - 1094
  • [4] Persistence of haemostatic response following gene therapy with valoctocogene roxaparvovec in severe haemophilia A
    Pasi, K. John
    Laffan, Michael
    Rangarajan, Savita
    Robinson, Tara M.
    Mitchell, Nina
    Lester, Will
    Symington, Emily
    Madan, Bella
    Yang, Xinqun
    Kim, Benjamin
    Pierce, Glenn F.
    Wong, Wing Yen
    HAEMOPHILIA, 2021, 27 (06) : 947 - 956
  • [5] Real-world data of prophylaxis with emicizumab in children and adolescents with severe haemophilia: A single centre experience
    Michalopoulou, A.
    Dettoraki, A.
    Karelioti, H.
    Thymianou, S.
    Papageorgiou, N.
    Stamati, I.
    Saslis, S.
    Kapsimali, Z.
    Pergantou, H.
    HAEMOPHILIA, 2024, 30 : 61 - 61
  • [6] Real-world experience on the tolerability and safety of emicizumab prophylaxis in paediatric patients with severe haemophilia A with and without FVIII inhibitors
    Hassan, Eman
    Jonathan, Lancashire
    Jayashree, Motwani
    HAEMOPHILIA, 2021, 27 (06) : E698 - E703
  • [7] REAL-WORLD EFFICACY OF EMICIZUMAB PROPHYLAXIS IN PATIENTS WITH SEVERE HAEMOPHILIA A WITHOUT INHIBITORS: A REPORT FROM THE UK HAEMOPHILIA CENTRE DOCTORS' ORGANISATION
    Wall, C.
    Xiang, H.
    Palmer, B.
    Collins, P. W.
    Stephensen, D.
    Scott, M.
    Chalmers, E.
    Chowdary, P.
    Hall, G. W.
    Liesner, R.
    Hart, D. P.
    Shapiro, S.
    Talks, K.
    Fletcher, S.
    Hay, C. R.
    HAEMOPHILIA, 2021, 27 : 116 - 116
  • [8] EMICIZUMAB PROPHYLAXIS IN HAEMOPHILIA A WITH AND WITHOUT INHIBITORS: REAL-WORLD DATA FROM SLOVENIA
    Rener, K.
    Doma, S. Anzej
    Kotnik, B. Faganel
    Kitanovski, L.
    Fink, M.
    Zupan, I. Preloznik
    HAEMOPHILIA, 2021, 27 : 70 - 70
  • [9] Real-world experience of emicizumab prophylaxis in young children with haemophilia A in China: retrospective data from China
    Huang, Kun
    Liu, Guoqing
    Wu, Runhui
    Chen, Zhenping
    Zhen, Yingzi
    Wu, Xinyi
    HAEMOPHILIA, 2022, 28 : 50 - 50
  • [10] Real-world experience of emicizumab prophylaxis in children with severe haemophilia A: I year follow-up study in egypt
    Sherief, L.
    Hassan, A. S.
    Hamdy, M.
    Darwish, A.
    Nazim, A.
    Hussein, M. A.
    Elgendy, M. R.
    El-assy, O. A.
    HAEMOPHILIA, 2024, 30 : 121 - 121
12345